MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in two recent reports published by Ludlow Research. In both reports, Ludlow issued an upgrade research opinion on MetAlert with a valuation target of $1.00 to $1.25 per share. The upgrades were based on various factors, including MetAlert’s agreement with a major IoT connectivity company out of Germany, its expansion of medical devices for the aging and autism markets, ramp-up in SmartSole unit production to fulfill backorders, as well as elimination of toxic debt. “In recent months, MetAlert extinguished all of their toxic convertible notes from their balance sheet, which should now provide increased stability to their public float. The influx of new chips in Q4 2022 should significantly increase production of SmartSole units in early 2023. This ramp-up in production should help fulfill backorders currently in place and increase revenues in the coming months,” reads the latest update. “The elimination of toxic debt, improved guidance to their NFC operations, and launch of new medical devices geared towards the geriatric and autism health care markets now places the company in a much healthier position going forward into 2023.”
To view the full reports, visit https://ibn.fm/oMBMl and https://ibn.fm/5TUQ3
About MetAlert Inc.
MetAlert is a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, supported through a proprietary IOT enterprise monitoring platform and intellectual property portfolio. The company offers global end-to-end solutions of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications, utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. MetAlert is known for its game-changing and award-winning patented GPS SmartSole – think Dr. Scholl’s meets LoJack, the world’s first visible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert’s business model is built around technology innovation and the company holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in over 40 countries and is a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.